[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100429587":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":46,"responsibleParty":66,"collaborators":31,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":31,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":49,"whyStopped":31,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Hospital de Clinicas de Porto Alegre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Participants into the placebo group will receive the same treatment regimen, but with packets of the same appearance and size containing only vehicle.",[13],"Other: Placebo Comparator",{"label":15,"type":16,"description":17,"interventionNames":18},"Taurine","ACTIVE_COMPARATOR","Participants will receive 6 gy taurine divided into twice\u002Fday orally administration for 12 weeks.",[19],"Drug: Active comparator Taurine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Active comparator Taurine","Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g\u002Fpacket) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.",[15],[15],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Placebo Comparator","Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle",[9],null,[33],{"name":34,"affiliation":35,"role":36},"Beatriz D Schaan, PhD","Hospital de Clínicas de Porto Alegre","PRINCIPAL_INVESTIGATOR",[38,42],{"name":34,"role":39,"phone":40,"phoneExt":31,"email":41},"CONTACT","55 51 3359-8000","bschaan@hcpa.edu.br",{"name":43,"role":39,"phone":44,"phoneExt":31,"email":45},"Rosane Gomez, PhD","55 51 33082823","rogomez@hcpa.edu.br",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Hospital de Clínicas","RECRUITING","Porto Alegre","Rio Grande do Sul","90630090","Brazil","BR",{"type":56,"coordinates":57},"Point",[58,59],-51.23019,-30.03283,{"lat":59,"lon":58},[62,65],{"name":63,"role":39,"phone":64,"phoneExt":31,"email":41},"Beatriz D'agord Schaan, PhD","55+513359-8000",{"name":43,"role":39,"phone":44,"phoneExt":31,"email":45},{"type":67,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100429587","phase-2-taurine-effect-on-glycemic-lipidic-and-inflammatory-profile-in-individuals-with-type-2-diabetes-100429587",false,"NCT04874012","Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes","Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial","TAUGLIP-DM2","Inclusion criteria\n\n* Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;\n* Age over 30 years;\n* BMC equal to or above 18.5 kg\u002Fm2, without weight change in the last 3 months;\n* HbA1c between 7.5% and 10.5%.\n\nExclusion criteria\n\n* Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;\n* Pregnancy or lactation;\n* Chronic renal failure with glomerular filtration rate calculated by MDRD \\\u003C 30 mL\u002Fh;\n* Myocardial infarction in the last than 6 months\n* Current neoplasia;\n* Chronic use of glucocorticoids;\n* Bariatric surgery.","ALL","30 Years","80 Years",{"count":80,"type":81},94,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.",[87],"Diabetes Mellitus, Type 2",[89,90,91,92,93,94],"taurine","inflammation","glucose metabolism disorders","glycated hemoglobin","diabetes mellitus, type 2","amino acids","2025-09-15",{"date":97,"type":98},"2025-09-19","ACTUAL",{"date":100,"type":98},"2021-06-12",{"date":102,"type":81},"2025-12",{"name":5,"class":6},1]